Pr bouchard

Charles Edouard Brown Sequard (1817- 1894)

Science 1997

& GH

GH-IGF1-Insulin

• 1- Les données de la recherche sont sans equivoque.

INSULIN / IGFs Signaling

KO GHKO GHRHKO GHRKO KO IGF1KO IGF1-RKO IRS 1 & 2, PI3 K

Yeasts, caenorhabditis elegans, insects, mice & centenarial model

INSULIN / IGFs Signaling

Endocrine Reviews 2011

Des taux bas d’IGF1 sont associés à une longévité accrue

• Déficit en GH• KO des récepteurs de la GH• KO des récepteurs de l’IGF1(Bartke A

Cur Top Dev Biol 63:189, 2004)

+ 18 %

GH-IGF1-Insulin

• 2- Chez l’homme…

Endocrine Reviews 2010, 31: 301-342.

JCEM 18: 901- 903, 1958

NATURE 1979

There is now a substantial body of evidence that indicates that GH Replacement Therapy has a beneficial effect upon many parameters:

Body composition improves, lean mass increases, and fat mass decreases sgnificantly.

-Fasting lipid profile improves with reduction on total cholesterol, LDL while HDL increases.

-GHT improves endothelial function as well as the markers of inflammation

- Carotid IMT also demonstrates a significant improvement during therapy

Swerdlow AJ, Higgins CD, Adlard P, Preece MA 2002 Risk of cancer in patients treated with17 human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 360:273-277

-Insulin resistance is Increased

-There is no data demonstrating that GHT reduces cardiovascular mortality in hypopituitary adults

- In addition: cancer risk may be increased

HOWEVER

JCEM 2012

SAGhE : Safety and Appropriateness of Growth hormone treatments in Europe

Les Fondamentaux

• « Apprends d’hier, vis pour aujourd’hui, espère pour demain.

• L’important est de ne jamais arrêter de poser des question. »

Albert Einstein

www.ice-ece2012.com